Avadel Pharmaceuticals plc discloses zero interests in relevant securities as offeree under Irish Takeover Panel rules.
Quiver AI Summary
Ap9 FORM 8.1(a) & (b) was issued by Avadel Pharmaceuticals plc on November 5, 2025, under the Irish Takeover Panel rules, indicating that the company is the offeree in an ongoing takeover situation. As of November 4, 2025, Avadel Pharmaceuticals disclosed no interests or short positions in its relevant securities, and specifically noted that no other parties to the offer were included in this disclosure. The document further details the shareholdings of the company's directors, collectively holding 794,959 shares, which comprises approximately 0.81% of the total issued ordinary share capital. Additionally, it mentions that there are no indemnity or other dealing arrangements or agreements relevant to the disclosed securities. The disclosure is part of regulatory requirements to provide transparency during the takeover process.
Potential Positives
- Disclosure of shareholdings of directors shows a vested interest in the company's performance, which may enhance investor confidence.
- All interests and short positions disclosed are notable for their transparency, indicating compliance with regulatory requirements.
- The absence of short positions may suggest potential stability or confidence in the company's future performance.
Potential Negatives
- The company disclosed that it holds no relevant securities or derivatives, indicating a lack of financial interest or confidence in its own stock.
- The directors listed hold only a small percentage of the company's total issued ordinary share capital, raising concerns about their investment and alignment with shareholder interests.
- Absence of any indemnity or dealing arrangements could suggest a lack of strategic engagement or support from influential parties.
FAQ
What is the date of the opening position disclosure?
The date of the opening position disclosure is November 5, 2025.
Who is the offeree in this disclosure?
The offeree in this disclosure is Avadel Pharmaceuticals plc.
What notable interests did directors have at the time of disclosure?
Directors had various interests, with a total of 794,959 ordinary shares held collectively.
Is there a Supplemental Form 8 attached?
No, there is no Supplemental Form 8 attached to the disclosure.
What is advised if the disclosure details are incorrect?
If incorrect, details should be corrected in a subsequent disclosure, clearly stating the corrections made.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AVDL Hedge Fund Activity
We have seen 93 institutional investors add shares of $AVDL stock to their portfolio, and 74 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC removed 2,460,203 shares (-18.1%) from their portfolio in Q2 2025, for an estimated $21,772,796
- VANGUARD GROUP INC added 1,659,609 shares (+42.5%) to their portfolio in Q2 2025, for an estimated $14,687,539
- BLACKROCK, INC. added 1,349,873 shares (+24.8%) to their portfolio in Q2 2025, for an estimated $11,946,376
- TWO SEAS CAPITAL LP added 1,208,625 shares (+24.4%) to their portfolio in Q2 2025, for an estimated $10,696,331
- TRI LOCUM PARTNERS LP added 1,014,456 shares (+inf%) to their portfolio in Q2 2025, for an estimated $8,977,935
- GEODE CAPITAL MANAGEMENT, LLC added 979,422 shares (+82.3%) to their portfolio in Q2 2025, for an estimated $8,667,884
- BANK OF AMERICA CORP /DE/ removed 973,857 shares (-87.1%) from their portfolio in Q2 2025, for an estimated $8,618,634
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$AVDL Price Targets
Multiple analysts have issued price targets for $AVDL recently. We have seen 5 analysts offer price targets for $AVDL in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- Ashwani Verma from UBS set a target price of $20.0 on 10/28/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $20.0 on 10/23/2025
- Marc Goodman from Leerink Partners set a target price of $18.5 on 10/23/2025
- Andrew Tsai from Jefferies set a target price of $20.0 on 10/22/2025
- Benjamin Burnett from Wells Fargo set a target price of $16.0 on 09/03/2025
Full Release
U.K. DISCLOSURE, Nov. 05, 2025 (GLOBE NEWSWIRE) --
Ap9
FORM 8.1(a) & (b)
(Opening Position Disclosure)
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE
1. KEY INFORMATION
| (a) Full name of discloser: | Avadel Pharmaceuticals plc |
|
(b)
Owner or controller of interests and short
positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. |
N/A |
|
(c)
Name of offeror/offeree in relation to whose
relevant securities this form relates:
Use a separate form for each offeror/offeree |
Avadel Pharmaceuticals plc |
| (d) Is the discloser the offeror or the offeree? | OFFEREE |
|
(e)
Date position held:
The latest practicable date prior to the disclosure |
4 November 2025 |
|
(f)
In addition to the company in 1(c) above, is the
discloser also making disclosures in respect
of any other party to the offer?
If it is a cash offer or possible cash offer, state “N/A” |
N/A |
2.
INTERESTS AND SHORT POSITIONS
If there are interests and positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Ap10
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates (Note 1)
| Class of relevant security: (Note 2) | ||||
| Interests | Short positions | |||
| Number | % | Number | % | |
| (1) Relevant securities owned and/or controlled: | NIL | - | NIL | - |
| (2) Cash-settled derivatives: | NIL | - | NIL | - |
| (3) Stock-settled derivatives (including options) and agreements to purchase/ sell: | NIL | - | NIL | - |
| Total: | NIL | - | NIL | - |
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. INTERESTS AND SHORT POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY MAKING THE DISCLOSURE
| Details of any interests and short positions (including directors’ and other employee options) of any person acting in concert with the party making the disclosure: | ||||
| The directors of the Offeree detailed in the table below (together with their connected persons under Rule 3.3(b)(ii) of Part A of the Irish Takeover Rules) have the following interests in the Offeree: | ||||
| Director | Class of Relevant Security | Number of ordinary shares held at midnight on 4 November 2025 | Percentage of total issued ordinary share capital (rounded) (%) | Total number of ordinary shares underlying outstanding stock options, restricted share units and other subscription rights |
| Peter Thornton | Ordinary shares of US$0.01 each | 104,055 | 0.11 | 252,000 |
| Linda Palczuk | Ordinary shares of US$0.01 each | 67,900 | 0.07 | 277,000 |
| Geoffrey Glass | Ordinary shares of US$0.01 each | 155,979 | 0.16 | 252,000 |
| Eric Ende | Ordinary shares of US$0.01 each | 208,900 | 0.21 | 260,057 |
| Gregory Divis | Ordinary shares of US$0.01 each | 169,100 | 0.17 | 2,922,000 |
| Mark McCamish | Ordinary shares of US$0.01 each | 78,025 | 0.08 | 302,000 |
| Naseem Sajjid Amin | Ordinary shares of US$0.01 each | 11,000 | 0.01 | 82,500 |
| TOTAL | - | 794,959 | 0.81 | 4,347,557 |
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
| Interests and short positions held by Folio Investments Inc., an entity under the same control as Goldman Sachs & Co. LLC, presumed concert party of the offeree | ||||
| Class of relevant security: Ordinary shares of $0.01 each | ||||
| Interests | Short positions | |||
| Number | % | Number | % | |
| (1) Relevant securities owned and/or controlled: | 20 | 0.00 | 0 | - |
| (2) Cash-settled derivatives: | 0 | 0.00 | 0 | - |
| (3) Stock-settled derivatives (including options) and agreements to purchase/ sell: | 0 | 0.00 | 0 | - |
| Total: | 20 | 0.00 | 0 | - |
Ap11
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
| Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it: |
| Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” |
|
None
|
(b)
Agreements, arrangements or understandings relating to options or derivatives
| Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. |
|
None
|
(c)
Attachments
| Is a Supplemental Form 8 attached? | YES/NO |
| No |
| Date of disclosure: | 5 November 2025 |
| Contact name: | Jerad Seurer |
| Telephone number: | +1 636-730-1420 |
Public disclosures under Rule 8.1 of the Rules must be made to a Regulatory Information Service.
Ap12
NOTES ON FORM 8.1(a) and (b)
1. See the definition of “interest in a relevant security” in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) of Part B of the Rules.
2. See the definition of “relevant securities” in Rule 2.1 of Part A of the Rules.
3. If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.